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Abstract
RNA interference (RNAi) is a natural cellular mechanism to silence gene expression and is predominantly mediated by
microRNAs (miRNAs) that target messenger RNA. Viruses can manipulate the cellular processes necessary for their
replication by targeting the host RNAi machinery. This study explores the effect of human T-cell leukemia virus type 1
(HTLV-1) transactivating protein Tax on the RNAi pathway in the context of a chromosomally integrated viral long terminal
repeat (LTR) using a CD4
+ T-cell line, Jurkat. Transcription factor profiling of the HTLV-1 LTR stably integrated T-cell clone
transfected with Tax demonstrates increased activation of substrates and factors associated with chromatin remodeling
complexes. Using a miRNA microarray and bioinformatics experimental approach, Tax was also shown to downregulate the
expression of miRNAs associated with the translational regulation of factors required for chromatin remodeling. These
observations were validated with selected miRNAs and an HTLV-1 infected T cells line, MT-2. miR-149 and miR-873 were
found to be capable of directly targeting p300 and p/CAF, chromatin remodeling factors known to play critical role in HTLV-
1 pathogenesis. Overall, these results are first in line establishing HTLV-1/Tax-miRNA-chromatin concept and open new
avenues toward understanding retroviral latency and/or replication in a given cell type.
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Introduction
Human T-cell leukemia virus type 1 (HTLV-1) was the first
human retrovirus isolated from a patient with T-cell lymphoma
[1,2] and is known to cause two major diseases: a progressive
lymphoma designated adult T-cell leukemia (ATL) [3,4] and a
neuroinflammatory disease called HTLV-1-associated myelopa-
thy, also referred to as tropical spastic paraparesis [5,6]. Although
about 10 million to 20 million people are infected with HTLV-1
worldwide [7], only 5% of such infected individuals develop ATL
or tropical spastic paraparesis, whereas 95% remain asymptomatic
carriers [8,9,10]. It is still not fully understood why only a small
percentage of the infected individuals develop the disease [11].
The virus preferentially targets CD4
+ T cells [12], but other
secondary cell types such as CD8
+ T cells [13], cells of the
monocyte-macrophage lineage, and dendritic cells [14,15] as well
as those belonging to the resident CNS cell population [16] are
also known to be infected. Once the virus genome has been
introduced into the target cell, it is reverse transcribed and
integrated semi-randomly into the host genome as a provirus [17].
The provirus, like eukaryotic DNA, is coiled with histone and non-
histone proteins to form the nucleosome that comprises the basic
unit of chromatin [18] and thus functions as a surrogate cellular
transcriptional unit. HTLV-1 exists primarily as a cell-associated
provirus that is transmitted primarily through cell-to-cell contact
[11] via a virological synapse [19,20].
Gene expression following proviral integration is a crucial stage
in the HTLV-1 retroviral life cycle, which depends on the viral
transcriptional transactivating protein Tax [21,22] and specific
cellular transcription factors during both infection and viral
reactivation from latency [23,24]. The 40-kDa Tax protein is
involved in upregulating HTLV-1 gene expression by interaction
with three 21-base pair (bp) Tax-responsive elements (TRE)
located within the U3 region of the viral promoter or long terminal
repeat (LTR) [25,26,27]. Each TRE comprises domains A, B, and
C [28] with the central B region consisting of a conserved 8-
nucleotide core sequence that closely mimics a cyclic AMP-
responsive element (CRE) and is flanked by 59 and 39 G/C rich
sequences [29]. Tax activates transcription by interfacing with a
number of cellular transcription factors: CRE binding protein
(CREB) and serum response factor (or p67
SRF) to the CRE
[30,31]. Tax interacts with dimeric CREB as a homodimer
forming a ternary complex that in turn facilitates the stabilization
of a CREB/TRE complex [29,32]. Once stabilized, Tax
independently recruits two cellular coactivators, p300/CREB-
binding protein (p300/CBP) and p300/CBP-associated factor (P/
CAF), both of which bind two distinct regions in the amino- and
carboxyl-terminus of Tax, respectively, eventually activating
transcription by histone acetylation through chromatin remodeling
[33,34,35,36]. In addition, Tax reduces histone protein and
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cell lines [37,38].
However, most of the investigations highlighting the importance
of the cellular transcription factors in HTLV-1 Tax-mediated
LTR activation [30,39,40,41,42] and the ability of Tax protein to
interact with these factors independently [33,36,43] have been
performed using transiently transfected viral reporter plasmids or
in cell lines that otherwise do not represent the primary target for
HTLV-1 in vivo. Further studies with HIV-1 indicated that the
integrated provirus differs from a transfected viral plasmid both
physically [44] and in the requirement of certain cellular factors,
especially those belonging to the chromatin remodeling histone
acetyltransferase (HAT) family [45,46,47] or even the transcrip-
tional repressor domain [48]. These results demonstrate that
transient transfection studies may not convey the complete picture
by undermining the crucial role of chromosomal structure in
transcriptional regulation. Hence, to better understand viral gene
regulation and the complex interplay between the integrated
provirus, host cellular transcription factors, and the viral Tax
protein during the course of infection and reactivation following
latency, it is imperative that such studies be performed with the
stably integrated viral promoter formatted in the context of
cellular chromatin.
With respect to regulation of the HTLV-1 promoter, it has been
demonstrated that indeed a differential requirement exists for the
cellular transcription factors in the activation of stably integrated
versus transiently transfected LTR [49]. Therefore, we decided to
examine Tax-mediated regulation of an integrated HTLV-1 LTR.
To this end, LTR stable integrants with a reporter luciferase gene
(LTR-luc) were generated in the Jurkat cell line, representative of
the natural target CD4
+ T cells, to characterize the intricacies
involved in the interplay between the integrated provirus, cellular
transcription factors and Tax protein. Herein, we demonstrate the
successful generation of Jurkat T-cell clones harboring stably
integrated HTLV-1 LTR-luc. Further, to investigate the compar-
ative activation/repression of cellular factors between stably
integrated and transiently transfected LTR in the absence and
presence of Tax, a high-throughputtranscriptionfactor analysis was
performed using protein-DNA array technology. Many substrates
and factors associated with the two major chromatin-remodeling
complexes, SWI/SNF and HATs, were activated in the stably
integrated clones following transfection with Tax. To explore the
observed heightened activation of factors necessary for chromatin
remodeling complexes, we explored the upstream microRNA
(miRNA) regulatory pathway by miRNA microarray. Herein, a
global downregulation in the expression of cellular miRNAs in the
HTLV-1 LTR-luc stably integrated CD4
+ T-cell clone was
observed in the presence of Tax, implying the ability of Tax to
modulate the cellular miRNA machinery. When compared to
results presented with the transcription factor array, many of the
downregulated miRNAs were found to target the mRNA coding for
the P/CAF and p300 HAT family members, suggesting a role for
Tax in downregulating the expression of cellular miRNAs that are
in turn involved in suppressing the expression of factors involved in
chromatin remodeling. The results presented herein demonstrate
that the Tax protein can modulate the cellular miRNA machinery
and downregulate the expression of miRNAs that could be involved
in regulating the chromatin remodeling factors.
Materials and Methods
Cell culture
Jurkat CD4
+ T cells (ATCC# TIB-152) and the HTLV-1-
producing rat cell line TARL-2 [50] were propagated at 37uC with
5% CO2 and 90% relative humidity in RPMI-1640 (Mediatech,
Herndon, VA) supplemented with penicillin (Mediatech, 100 U/
ml), streptomycin (Mediatech, 100 mg/ml), sodium pyruvate
(Mediatech, 1.0 mM), HEPES buffer (Mediatech, 10 mM),
0.45% glucose (Mediatech), and 10% fetal bovine serum (Thermo
Fisher Scientific, Waltham, MA).
Plasmids
The plasmids, pCMV-Tax and the pGL3-based HTLV-1 LTR
luciferase reporter vector pU3R-luc, were kindly provided by Dr.
Kuan-Teh Jeang (NIH, Bethesda, MD) and have been described
previously [51]. The plasmids pGL3 basic and pUC18 and
parental pCMV4 plasmids were obtained commercially (Promega,
Madison, WI). The plasmid pRSV-neo encoding the selectable
marker for neomycin resistance was obtained from ATCC
(Manassas, VA; catalog #37198).
Stable integration of HTLV-1 LTR in Jurkat cells
Jurkat cells were plated in 100-mm culture plates with
antibiotic-free medium at a seeding density of 5610
6 cells per
plate. Cells were co-transfected with 8 mg of pU3R-luc plasmid
and 0.8 mg of pRSV-neo plasmid using Lipofectamine (Invitrogen,
Carlsbad, CA). Twenty-four hours post-transfection, the cells were
transferred to antibiotic-containing medium. On the third day,
G418 (Geneticin; Invitrogen) was added to the cell culture at a
concentration of 500 mg/ml. After 15 days of G418 selection,
several single clones were isolated by performing serial dilutions
and were propagated to confluence.
Luciferase assay
Cell lysates were prepared from 1610
6 cells using 50 mlo f
16Passive Lysis Buffer (Promega, Madison, WI), and luciferase
activity was assayed using the luciferase assay system (Promega) on
the Glomax 96 microplate luminometer (Promega).
Polymerase chain reaction
To verify integration of the HTLV-1 LTR-luc in the clones,
polymerase chain reaction (PCR) was performed to detect both the
LTR and luciferase gene using the following primer sequences: for
(a) HTLV-1 LTR (F:59GACCAAGGCTCTGACGTCTC39;
R:59TTTTGAGGTGAGGGG TTGTC39) and (b) luciferase
open reading frame (F:59ATGGAAGACGCCAAAAACATAA-
AG AAAGG39; R:59TAGAATTACACGGCGATCTTTCCG-
C39) with amplicon sizes of 183 bp and 1.6 kb, respectively. The
standard PCR reaction involved using 45 ml of PCR Supermix
(Invitrogen), 10 mM each of forward and reverse primer, and
50 ng of DNA in a total volume of 50 ml. The thermal cycling
conditions comprised an initial activation step at 95uC for 2 min
followed by 35 cycles involving denaturation at 95uC for 30 sec,
annealing at 54uC for 30 sec, extension at 72uC for 1 min, and a
final extension at 72uC for 10 min.
Southern blot hybridization
Genomic DNA was extracted from stably transfected Jurkat
cells using the Wizard SV Genomic DNA extraction procedure
(Promega), and 10 mg of the extracted DNA was digested
overnight with EcoRI and amplified for the luciferse gene by
PCR. Resolved PCR products were blotted onto a nylon
membrane. The membrane was hybridized with a luciferase open
reading frame fragment as probe and excised from the pGL3
vector using restriction enzymes NcoI and XbaI [49]. The probe
was labeled with [a-
32P] dCTP using the GE Amersham
Rediprime II Labeling System (GE Healthcare Biosciences Corp,
RNAi and Regulation of the HTLV-1 Promoter
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screened, and scanned on Amersham Biosciences STORM 820
using the STORM scan software, and the pictures were analyzed
using ImageQuant software (GE Healthcare Biosciences, Piscat-
away, NJ).
Real-time PCR
To generate standard curves, DNA was extracted from the
Jurkat cells for b-actin and TARL-2 for LTR. Because the single
Jurkat cell has two copies of b-actin, we calculated that 1 ng of
DNA contains 333 copies of the b-actin gene, whereas for TARL-
2, which is an HTLV-1-infected cell line with a single copy of
HTLV-1 proviral DNA [50], 1 ng of DNA contains 167 copies of
LTR [52]. The extracted DNA samples were serially diluted to get
10
5,1 0
4,10
3,1 0
2, 10, and 1 copy for both b-actin and LTR. Real-
time PCR was performed on an ABI Prism 7300 Sequence
Detector (Applied Biosystems, Foster City, CA). The standard
real-time PCR reaction using SYBR Green I consisted of 15 ml
SYBR Green PCR Master Mix (Applied Biosystems), 10 mM each
of forward and reverse primers (IDT, Coralville, IA), and 10 mlo f
DNA in a total volume of 30 ml. The thermal cycling conditions
comprised an initial activation step at 95uC for 10 min followed by
40 cycles including denaturation at 95uC for 15 s and annealing
and extension at 60uC for 1 min. The following primers were used
for HTLV-1 LTR (F:59GACCAAGGCTCTGACGTCTC39;
R:59TTTTGAGGTGAGGGGTTGTC39) and b-actin (F:59CA-
GCGGAACCGCTCATTGCCAATGG39; R:59TCACCCACA-
CTGTGCCCATCTACG A39). Experiments were performed in
duplicate for each data point. Dissociation or melting curve
analysis was implemented to ensure the presence of a single peak
at the correct melting temperature. The standard curves for b-
actin and LTR were used with a coefficient of correlation, r
2, being
greater than 0.996 for both. From the standard curves, the CT
values for LTR and b-actin for different clones were obtained and
used to calculate the copy number. Copy number per cell for each
clone was calculated from the formula (copy number of LTR)/
(copy number of actin/2)610
2, and expressed as the number of
HTLV-1 integrated copies per 100 cells.
Transient transfections
Five million cells per well of the selected clone were plated in a
100-mm tissue culture dish (BD Labware, Franklin, NJ) in
antibiotic-free medium the day before transfection. Transient
transfection was performed using FuGene 6 transfection reagent as
described by the manufacturer (Roche, Indianapolis, IN). For
clones with a stably integrated LTR, the transfection setup
included 6 mg of pCMV4 (empty expression vector) or 1 mgo f
pCMV-Tax and 5 mg of pUC18. For cells with a transiently
transfected LTR, the setup included 1 mg of pCMV4 and 5 mgo f
pU3R-luc or 1 mg of pCMV-Tax and 5 mg of pU3R-luc. The
indicated amounts of pUC18 plasmid DNA were used to obtain an
equal amount of total DNA in each experimental design. Cells
were harvested 24 h post-transfection and processed to obtain cell
extracts (luciferase assay), nuclear extracts (transcription factor
array), and total miRNAs (miRNA microarray).
Protein-DNA transcription factor array
Nuclear extracts were isolated from 1610
6 transfected cells as
described by the manufacturer (Panomics, Fremont, CA) and the
protein content was determined using the Bradford assay (Bio-Rad
Laboratories, Hercules, CA). The protein-DNA array membranes
(PD Array I, Panomics) were pretreated at 42uC overnight with
hybridization buffer. The nuclear extract was labeled with the
TranSignal Probe mix as described by the manufacturer
(Panomics). The labeled probe was eluted and hybridized to the
array membranes. The bound probe was detected by treating with
streptavidin-horseradish peroxidase substrate after hybridization.
The membranes were then exposed using the chemiluminescence
imaging system (Fluorchem Imager, Cell Biosciences, Santa Clara,
CA), and the spots were analyzed using ImageQuant software (GE
Healthcare Biosciences). Spots from each membrane were
normalized to their respective positive controls after background
subtraction.
miRNA isolation, labeling, and hybridization
Total miRNA was isolated as described by the manufacturer
using the PureLink miRNA isolation procedure (Invitrogen). After
the miRNA was quantitated, poly (A) tail was added to the
miRNA followed by ligation to a DNA polymer already labeled
with Alexa Fluor dye using the NCode miRNA Rapid Labeling
module (Invitrogen). Stably integrated clone C5 transfected with
pCMV-Tax control was labeled with Cy5 (Alexa Fluor 635), and
the clone C5 transfected with pCMV was labeled with Cy3 (Alexa
Fluor 532). The purified tagged miRNA was hybridized to an
NCode Human miRNA Microarray V3 (Invitrogen), which is an
epoxy-coated glass slide printed with miRNA probes targeting all
of the known human miRNAs in the miRBase Sequence database,
release 10.0, in an antisense orientation. Following overnight
hybridization, the array was washed. Within 30 min of the final
wash, the array was scanned and analyzed on the microarray
scanner Genepix 4000A (Axon Instruments, Molecular Devices,
Sunnyvale, CA) at 635 nm and 532 nm.
Validation of miRNA array data and confirmation of
target mRNAs
From the miRNA array data, miR-149 and miR-873, that were
found to be down regulated by 0.2-fold, were selected and
subjected to further confirmation in an HTLV-1-infected T cells
line MT-2. Total RNA was extracted from by using the TRIzol
reagent (Life Technologies) and subjected to cDNA preparation
using the TaqMan MicroRNA RT kit (Applied Biosystems). The
standard real time PCR reaction was set up using RT primers
specific for miR-135b, miR-149 or miR-873 provided in the
microRNA assay. The thermal cycling conditions comprised an
initial activation step at 95uC for 10 min followed by 40 cycles
including denaturation at 95uC for 15 s and annealing and
extension at 60uC for 1 min.
Following confirmation of miRNA presence in Jurkat cells and
their downregulation in MT-2 cells, specific miRNA mimics
(200 pg) were transfected in these cells using Lipofectamine as per
manufacturer’s instruction (Invitrogen). Thirty-six hour post-
transfection, one half of the transfected cells was harvested and
processed to obtain total cell lysates using M-PER Mammalian
Protein Extraction Reagent (Pierce, USA). The other half of the
cells were washed and resuspended in fresh medium. After
additional 2–3 days, supernatants were collected to carry out
HTLV-1 p19 ELISA (ZeptoMetrix Corp., Buffalo, NY, USA) in
order to assess the levels of viral progeny production. Western blot
analysis was performed to assess the effect of miRNA mimics on
target mRNAs (p300 and p/CAF). Total cell lysates were resolved
by SDS-PAGE and transferred to a PVDF membrane. The blots
were blocked for 1 h with Odyssey blocking buffer (Licor, Lincoln,
USA), and rinsed with PBST (PBS+0.05% Tween-20, once for
10 min and twice for 5 min). The membranes were then
incubated with anti-p300 and anti-p/CAF monoclonal antibodies
(each 1:1000 dilution, Abcam, Cambridge, USA) for 2 h at room
temperature and rinsed with PBST as before followed by 1 h
incubation with an IRDy800-conjugated anti-rabbit and
RNAi and Regulation of the HTLV-1 Promoter
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Signals were detected by Licor Pearl Pulse Imager.
Results
Construction of CD4
+ T-cell line with stably integrated
HTLV-1 LTR-luc
Most previously published studies concerning the regulation of
the HTLV-1 promoter have relied on transient transfection of
LTR-containing plasmids into a variety of different target cells.
The structural conformation, basal transcriptional activity, and
requirement for cellular transcription factors with regard to the
integrated chromatin-associated HTLV-1 LTR are different from
a transiently introduced LTR plasmid as observed in CHOK1 and
HeLa cell types [49]. Moreover, each cell type has different
endogenous levels of transcription factors, thereby introducing
another variable [49]. Therefore, to better understand the
regulation of the viral promoter when integrated into the genome
of the clinically relevant CD4
+ T cell, we constructed a stably
integrated HTLV-1 LTR-luc reporter in the CD4
+ T-cell line,
Jurkat.
The Jurkat CD4
+ T cells were cotransfected with the HTLV-1
LTR-luc (pU3R-luc)- and the antibiotic selection marker (pRSV-
neo)-containing plasmids using the Lipofectamine transfection
reagent and then selected for G418 (Geneticin) resistance for 15
days. A stably integrated control clone (without the HTLV-1 LTR)
was also derived by co-transfecting Jurkat cells with the pGL3-
basic and pRSV-neo plasmids. After the selection period, 25
clones of Jurkat CD4
+ T cells were isolated by serial dilution and
screened for integrated pU3R-luc with five representative clones
selected for further analysis. As shown in Fig. 1, different levels of
basal luciferase expression were observed across the five
representative clones in the initial screening process with
expression values ranging from lowest (202 relative light units
for clone 1) to highest (1385 relative light units for clone 5). The
wide range in the luciferase expression was likely due to the
different sites of integration of the HTLV-1 LTR-luc in the host
genome. Previous studies have shown that integration into a
transcriptionally active site will allow for a greater LTR-mediated
transcription of the luc gene with a higher luciferase expression
compared to the integration in a transcriptionally inactive region
[53,54,55]. The control clone shown in Fig. 1A represents
luciferase expression from the cell lysate of a Jurkat control clone,
which has the luciferase open reading frame but no promoter
region to drive the luciferase expression. All other individual stably
integrated Jurkat clones were propagated separately to maintain
long-term homogeneity. To rule out the possibility of a mutation
within the integrated viral promoter being responsible for the
observed variation in the LTR activity in the clones, the five clones
were PCR-amplified using the primers RV3 and GL2 with
specificity for the insert (integrated HTLV-1 LTR-luc) within the
multiple cloning site of the pGL3 vector and sequenced
(GENEWIZ, Inc, South Plainfield, NJ). The sequence for each
clone was then compared to the original LTR sequence within the
known HTLV-1 genome (NCBI accession number AF139170)
[56]. The sequencing results demonstrated complete similarity
with regard to the integrated HTLV-1 LTR-luc sequences from all
five clones as compared to the original LTR sequence, thus
eliminating the possibility of any mutation within the LTR being
responsible for the observed differences in luciferase expression
(data not shown). The analysis of clones with luciferase expression
values below or equal to those of the control was discontinued.
After selecting the G418-resistant and luciferase-expressing
clones, HTLV-1 LTR-luc integration into the genome of the
Jurkat clones was confirmed both qualitatively and quantita-
tively. Qualitative verification was performed with all five clones
by PCR using the HTLV-1 LTR primers (product size 183 bps)
confirming its presence (Fig. 1B). Similar results were obtained
when Southern blot hybridization was performed on the PCR-
amplified luciferase product using a luciferase probe, with a
stronger signal for clone C5, whereas a weaker signal was
observed for the remaining clones (Fig. 1B). These results clearly
indicate the presence of an integrated HTLV-1 LTR-luc in all
five clones by verifying independently the presence of both LTR
and luciferase genes. For quantitative assessment, real-time
PCR was performed to calculate copy numbers of the integrated
HTLV-1 LTR in all five clones after generating standard curves
for both b-actin and LTR using both the Jurkat and TARL-2
cell lines, respectively. As shown in Fig. 1C, approximately two
and three copies of the integrated provirus per cell were
detected in clones C3 and C5, respectively. The remaining
clones (C1, C2, and C4) had at least 1 copy per cell (Fig. 1C).
Overall, the results to date indicate that the Jurkat clones
selected after generation of stable integrants demonstrate
successful integration of the HTLV-1 LTR-luc. Unlike the
many copies of HTLV-1 LTR integrants observed in CHOK1
and HeLa [49], the results obtained with Jurkat cells were
probably different because the transfection efficiency of Jurkat
cells is much lower than that of either CHOK1 or HeLa. The
results obtained with the HTLV-1 LTR Jurkat cell clones were
more similar to those obtained with infected T-cell clones
examined ex vivo that preferentially contain a singly integrated
provirus [57]. Moreover, asymptomatic HTLV-1-infected
individuals have low proviral loads (2–3 copies per 100 cells)
in peripheral blood mononuclear cells, suggesting low integra-
tion efficiency in T cells [58,59,60]. Based on the results
obtained and the fact that infected T-cell clones have a low
proviral DNA load, experimental attention was focused on
clones 1, 2, and 4. We pooled the selected clones (clones 1, 2,
and 4), thereby generating a mixed population of stably HTLV-
1 LTR transfected CD4
+ T cells, representative of the infected
cell populations found in vivo. All subsequent transfection,
transcription factor profiling, and miRNA array analyses were
performed using this mixed pool of selected clones.
Effect of Tax on the integrated HTLV-1 LTR activity and
cellular transcription factors
To perform a comparative analysis and better understand the
regulation of the stably integrated versus transiently transfected
HTLV-1 LTR in the absence and presence of Tax in the context
of cellular transcription factors representative of the natural host
cell target, the CD4
+ T cell, we performed transient transfections
with a Tax-expressing plasmid in the pooled stably integrated
Jurkat cell clones and co-transfections with both HTLV-1 LTR
and Tax-expressing plasmids in parental Jurkat cells. The stably
integrated pooled Jurkat mixed cell clones were transiently
transfected with either pCMV4 (empty expression vector) or
pCMV-Tax (Tax expression vector), whereas Jurkat was tran-
siently transfected with either pU3R-luc (HTLV-1 LTR expres-
sion vector) or co-transfected with pU3R-luc and pCMV-Tax. All
transfectants were harvested independently after 24 h, and the
cellular (for luciferase assay) and nuclear (for transcription factor
analyses) extracts were processed as described. The luciferase
expression from the cell lysate of pooled stably HTLV-1 LTR
integrated Jurkat T-cell clones (Fig. 2A) and the transiently
transfected parental Jurkat cell line (Fig. 2B) indicate approx-
imately a 1000-fold significant increase (p,0.001) in expression of
the stably integrated reporter luciferase gene when transfected
RNAi and Regulation of the HTLV-1 Promoter
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drive luciferase expression via the integrated viral promoter. This
finding also validates the functional status of the integrated viral
promoter. Similarly, we noted a significant increase (p,0.001) in
luciferase expression with the transiently transfected viral promot-
er when transfected with Tax.
Figure 1. Screening of HTLV-1 LTR-luc stable integrants. (A) Luciferase activity in stably integrated HTLV-1 LTR Jurkat clones was measured in
terms of relative light units. Control represents the luciferase activity from the cells that were stably integrated with pGL3-basic vector and pRSV-neo.
Each value shown represents the average of duplicate transfection reactions and is representative of at least two independent experiments. Error bars
indicate standard deviation (6) from one representative experiment. (B) For verifying HTLV-1 LTR-luc integration, all five clones (C1–C5) were
examined and confirmed qualitatively for HTLV-1 LTR-luc integration for both LTR and luciferase genes independently by PCR amplification of LTR
with product size 183 bp and Southern blot hybridization using luciferase probe following PCR amplification of luciferase gene with product size
1.6 kb. The control clone represents the Jurkat clone stably integrated with pGL3-basic vector and pRSV-neo in the absence of the HTLV-1 LTR. The
positive control in each case is the pU3R-luc plasmid. (D) For quantifying HTLV-1 provirus copy numbers by real-time PCR in the stably integrated
clones, all five clones (C1–C5) were selected for real-time PCR analysis to determine the copy number of copies of the integrated LTR per 100 cells.
Standard curves for b-actin and the HTLV-1 LTR were generated from Jurkat and TARL-2 cell lines, respectively, with the coefficient of correlation, r
2,
being greater than 0.996 for both.
doi:10.1371/journal.pone.0034490.g001
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that can lead either to viral replication and proliferation or to a
state of dormancy/latency. To evaluate the impact of Tax on
cellular transcription factors and signaling pathways in the newly
generated HTLV-1 LTR stable T-cell integrant versus a T cell
transiently transfected with the HTLV-1 LTR, we performed
high-throughput analysis on various cellular transcription factors.
We used a DNA-protein array that offered the advantage of
analyzing multiple transcription factors at once as opposed to
individual factors by electrophoretic mobility shift assays. The
transcription factors associated with both stably integrated and
transiently transfected LTRs, which are characteristic of the major
pathways involved in HTLV-1 pathogenesis, were identified, and
their relative levels were analyzed. Many of the major factors
(CREB, Sp1, C/EBP, and NFAT), their interacting proteins as
well as those involved in the JAK/STAT and TGF-b signaling
pathways, were either activated or repressed following Tax
expression (Table 1). The factors STAT3 and SMAD3/4 were
activated in stable integrants, implying involvement of both the
JAK/STAT and TGF-b pathways. Because a stably integrated
LTR would have a preferential requirement for factors involved in
chromatin remodeling, the substrates (E2F1, GATA, and TFIID)
and factors (members of nuclear receptor family) for the two main
groups of chromatin remodeling complexes, HAT and SWI/SNF,
respectively, were highly activated in the stable integrants. Figure 3
explains and compares the importance of chromatin remodeling
machinery under stably integrated and transiently transfected
HTLV-1 LTR setting. It also highlights potential new players in
this process. As projected, there is increased need for chromatin
remodeling factors and their substrates in stably integrated LTR.
However, in case of transiently transfected LTR, the need for such
factors is reduced. The entire data from this analysis has been
deposited into the GEO database with an accession number
‘‘GSE33628’’.
miRNA profiling of Jurkat with stably integrated LTR in
the presence of Tax
Because of these compelling observations, we examined the role
of the Tax protein on the host miRNA machinery. The hypothesis
was that if Tax can modulate the host cellular miRNA machinery,
it should be able to downregulate the expression of those miRNAs
that are involved in repressing the mRNA for members of the
chromatin remodeling family. Based on results involving the
increased activation of chromatin remodeling substrates and
factors (Table 1), we theorized that the Tax protein could act
upstream by regulating the expression of miRNAs that target
mRNAs destined to be translated into chromatin remodeling
factors. This hypothesis was strengthened by a study highlighting
the ability of HIV-1 to suppress the expression of a miRNA linked
to P/CAF during viral replication [61].
A miRNA microarray was performed to determine if HTLV-1
Tax can modulate the cellular miRNA machinery and result in the
suppression of miRNAs linked to the chromatin remodeling
enzymes (P/CAF and p300). The miRNAs were isolated 24 h
after transfection of stably integrated pooled clones that were
either transfected with pCMV-Tax or the empty plasmid pCMV
(control). Each microarray experiment was performed in dupli-
cate, and only miRNAs that were consistently upregulated/
downregulated in both slides were examined. The miRNAs that
displayed changes in expression levels by more than 2.0 or less
than 0.5 were short-listed for further analysis. The fold-change is
derived from the ratio of means for Cy5/Cy3, where cell lines with
stably integrated LTR transfected with pCMV-Tax were labeled
with Cy5 whereas those transfected with pCMV were labeled with
Cy3. Analysis showed that Tax globally downregulated the
expression of cellular miRNAs in Jurkat carrying the stably
integrated HTLV-1 LTR-luc (Fig. 4). Overall, the expression level
of 41 miRNAs was altered: 35 miRNAs were downregulated
whereas six were upregulated after the introduction of the HTLV-
1 transactivating protein Tax into the system that had a stably
integrated LTR (Fig. 4). This initial observation suggested that
Tax does indeed modulate the miRNA machinery in some
manner. The next question was whether any of the downregulated
miRNAs were involved in the regulation of the HATs. Using the
Web-based tool MicroInspector [62], high-probability human
miRNAs that target P/CAF and p300 were screened with free
energy less than 220 kcal/mol at a hybridization temperature of
37uC. Of these, we found that eight miRNAs linked to the
regulation of P/CAF and 21 miRNAs linked to the regulation of
p300 were downregulated. These results corroborate the hypoth-
esis that Tax does indeed interact with the cellular miRNA
machinery to downregulate the expression of miRNAs that are in
turn involved in the regulation of HATs, so as to enable the virus
for transcribing viral proteins from the integrated LTR.
Figure 2. Verifying the functionality of the integrated HTLV-1
LTR-luc by determining the ability to respond to Tax. The stably
integrated pooled clone (clones C1, C2, and C4) was compared to
transiently transfected HTLV-1 LTR-luc Jurkat with respect to its ability
to respond to Tax by transiently transfecting both cell lines with either
pCMV (control) or pCMV-Tax. Luciferase activity was measured 24 h
post-transfection. (A) Stably integrated pooled clone versus the control
clone (without integrated viral promoter). (B) Transiently transfected
Jurkat clone with pU3R-luc versus control Jurkat (without transfected
viral promoter). Each value shown represents the average of duplicate
transfection reactions and is representative of two independent
experiments. Error bars indicate the standard deviation of one
representative experiment.
doi:10.1371/journal.pone.0034490.g002
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targeting p300 and p/CAF
For further analysis, we selected miR-149 and miR-873 that
showed 5-fold down regulation and could potentially target both
p300 and p/CAF (Fig. 4). Real-time PCR analysis specific to these
microRNAs was performed to detect and compare their
expression in control Jurkat T cell line cells as well as in active
virus producing cell line, MT-2. Amplification profiles of both
miRNAs clearly indicated their down regulation in MT-2 cells
confirming our miRNA array results (Fig. 5A). While calculating
the fold-change in expression by DDCt method, miR-149 showed
approximately 7-fold and miR-873 showed 5-fold down regulation
in MT-2 cells as compared to Jurkat (Fig. 5B) further
strengthening our microarray studies on clones.
The next question was whether miR-149 and miR-873 were
directly involved in regulating the HATs - p300 and p/CAF
thereby controlling chromatin remodeling in HTLV-1 infected
cells and aiding in viral replication. To test this, mimics of these
microRNAs were transfected in MT-2 and Jurkat cells and their
effect on the expression of putative target proteins was checked.
Also, MT-2 cell culture supernatant was scored for viral protein
(p19) production response prior to and after transfection. It was
observed in western blot analysis that p300 and p/CAF protein
levels were up regulated in MT-2 cells when compared with Jurkat
cells but were sharply reduced in the presence of miRNA mimics
(Fig. 6A). Jurkat cells showed only a slight down regulation in the
levels of p300 and p/CAF in response to mimics since the levels of
these proteins were already so low in these cells. With respect to
viral progeny production in the presence of mimics, supernatants
of MT-2 cells showed a drop in the level of viral protein p19 upon
transfection. Overall, these results confirmed the array data and
validated our hypothesis.
Discussion
Viral latency and reactivation are essential phases of the
retroviral life cycle that contribute to the persistence and
pathogenesis mediated by the virus. Although latency has been
well characterized in HIV-1 [63], much remains to be understood
Table 1. Transcription factor profiling of T cells containing stably integrated or transiently transfected HTLV-1 LTR.
Transcription Factor Fold Change (pCMV-Tax/pCMV)
Stable Transient
Nuclear Factors Upregulated
E2F1* E2F transcription factor 1 (substrate for p300) 2.4 0.7
GATA* GATA binding protein (substrate for p300 and P/CAF) 30 54
TFIID* Transcription factor II D (substrate for TAF1) 4.1 0.7
CREB cAMP responsive element binding protein 8.2 0.2
NF-E1 Nuclear factor (erythroid derived 1) 5.4 0.9
NF-E2 Nuclear factor (erythroid derived 2) 2.7 1.1
SMAD3/4 Small mothers against decapentaplegic 3/4 2.1 1.1
SP1 Stimulatory protein 1 15 1.2
SRE Serum responsive element 3.1 0.7
USF1 Upstream stimulatory factor 1 3.5 0.7
Downregulated
AP1 Activator protein ,0.1 ,0.1
BRN3 POU class 4 homeobox 2 0.1 0.7
CDP CCAAT displacement protein ,0.1 40
CEBP CCAAT enhancer binding protein ,0.1 ,0.1
c-Myb v-myb myeloblastosis viral oncogene homolog (avian) ,0.1 ,0.1
Cytoplasmic Factors Upregulated
GR** Glucorticoid receptor 3.5 0.9
PPAR** Peroxisome proliferator activated receptor 8.4 29
RAR** Retinoic acid receptor 3.4 1.5
RXR** Retinoid X receptor 3.7 1.5
VDR** Vitamin D receptor 3.2 0.3
NFAT Nucelar factor of activated T cells 41 1.8
STAT1 Signal transducer and activator of transcription 1 5.2 2.1
STAT3 Signal transducer and activator of transcription 3 3.7 0.3
Downregulated
PBX PBX knotted 1 homeobox 2 0.1 0.5
*Substrates for histone acetyltransferases (HATs) - p300, P/CAF, TAF1.
**Nuclear receptor (NR) family.
List of various cellular transcription factors that were differentially up- or downregulated in case of stably integrated or transiently transfected viral LTR.
doi:10.1371/journal.pone.0034490.t001
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mechanistic functioning of the viral promoter and its transactivat-
ing protein Tax have relied heavily on two major shortcomings:
first, the use of transient transfection studies to examine the
functional properties of the viral LTR, and second, the use of cell
lines that are not representative of the primary target cell
population in stable expression studies. A number of studies have
shown that activation of the chromosomally integrated viral
promoter is different from that of the transiently transfected
promoter for both HIV-1 and HTLV-1 [44,49]. Moreover,
because each cell type differs in its endogenous levels of various
cellular factors, it is important to compare relevant cell populations
to be able to accurately identify and elucidate the role of different
factors involved in the complex interplay between the virus and
host cell.
To address the impact of cellular chromatin on LTR-directed
viral transcription, we incorporated a stably integrated HTLV-1
LTR in the Jurkat cell line, which is representative of the clinically
relevant target CD4
+ T-cell population. Qualitative and quanti-
tative assessments were used to screen, verify, and select clones
from the initial population of stable integrants. Once the clones
were screened, they were subjected to further analyses involving
Figure 3. Mechanism to explain the differential requirements of cellular chromatin remodeling factors in stably integrated versus
transiently transfected HTLV-1 LTR. The major differences in the need for cellular chromatin remodeling factors between a stably integrated and
transiently transfected viral promoter are outlined. In the case of a stably integrated LTR, Tax mediates the increased recruitment of the chromatin
remodeling factors (HATs and SWI/SNF) and their substrates. In a transient transfection, the LTR is more readily accessible and thus exhibits a reduced
need for such factors.
doi:10.1371/journal.pone.0034490.g003
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presence of Tax, to identify transcription factors involved in viral
transcription and chromatin remodeling in the CD4
+ T-cell
population and the cellular miRNAs that might be differentially
modulated by Tax in the context of an integrated viral promoter
based on previous observations that each cell type is known to
have its own repertoire of miRNAs [64]. Therefore, this study
offers new insight into the regulation of the stably integrated
HTLV-1 LTR and a new perspective on the impact of Tax on
cellular miRNAs involved in the regulation of HATs in the
primary cell phenotype targeted by HTLV-1 during the course of
viral disease.
The transcription factor profiling following transfection with
Tax in stably integrated LTR versus transiently transfected LTR
cells yielded a number of expected results as well as some new
observations (Table 1). The relative levels of transcription factors
previously associated with HTLV-1-infected cells were highly
activated (CREB, Sp1, SRE, NFAT, STAT1, and SMAD3/4) or
repressed (C/EBP) in the stable HTLV-1 LTR-containing
integrants compared to the transient transfections, highlighting
the importance for the recruitment of such factors in the context of
a stably integrated LTR. Factors not previously characterized in
HTLV-1 LTR activation (BRN3 and PBX) had consistent levels in
both stable and transient LTR cells. In addition, some factors that
were highly activated (USF1, NF-E1, and NF-E2) or repressed
(CDP) in the stably integrated LTR have not been previously
documented to be involved in HTLV-1 infection. These factors
may be involved in HTLV-1 transcription but may have been
overlooked in earlier studies. The nuclear factors caught our
attention: E2F transcription factor 1 (E2F1), GATA binding
protein (GATA), and transcription factor IID (TFIID), as did the
cytoplasmic nuclear receptor (NR) family factors: glucocorticoid
receptor (GR), peroxisome proliferator-activated receptor (PPAR),
retinoic acid receptor (RAR), retinoid X receptor (RXR), and
vitamin D receptor (VDR). These factors serve as substrates or
factors for the chromatin remodeling complexes: the HATs and
SWI/SNF complexes, respectively [65]. However, two particular
factors (GATA and PPAR) were found at reduced levels in stable
compared to transient expression environments. Although the Tax
protein has been shown to repress transcription mediated by
certain members of the NR family (GR, RXR, and PPAR) in
HeLa and CV1 cells [66], the results obtained in this study
conflicted with the observed reduction in PPAR activation. From
the transcription factor analyses (Table 1), we observed marked
increases in the levels of members of the NR family. The NR
family is a group of ligand-activated transcription factors that are
located in inactive forms in the cytoplasm as part of a complex
with heat shock proteins [67]. Upon ligand binding, these
receptors dissociate from the complex and translocate to the
nucleus where they function as transcription factors [67]. The NR
family members GR, RAR, RXR, and VDR were upregulated in
the Tax-transfected stable LTR integrants (Table 1). In fact, the
GR and VDR promote remodeling activity by interacting with
subunits of the SWI/SNF complex [68,69].
RNAi is a cellular mechanism to silence gene expression and is
predominantly mediated by miRNAs that target messenger RNA.
The miRNAs are small endogenous RNAs (21–25 nucleotides)
that regulate cellular gene expression at the posttranscriptional
level, either by suppressing translation without affecting the
stability of the mRNA as in invertebrate animals or by mRNA
cleavage as mediated in plants [70]. Recent studies indicate the
ability of retroviruses to interfere with the cellular miRNA
regulatory pathway through the action of their transcriptional
transactivating protein [71,72] that can function as a suppressor of
RNA silencing. Viruses can manipulate the cellular processes
necessary for their replication and infection by targeting the host
RNAi machinery. The expression profile of miRNAs in HIV-1-
transfected human cells differs from that of control transfected cells
[73], implying the modulation of this pathway by viruses.
Bioinformatic tools have also highlighted the ability of inherent
human miRNAs to target many viruses including HIV-1 and
HTLV-1 [74]. However, as a counterbalance to the excitement
generated by studies elucidating the role of viral transactivators in
modulating host cellular miRNAs, some studies suggest otherwise
[75]. An miRNA expression profiling of HTLV-1-transformed T-
cell lines and primary peripheral blood mononuclear cells from
Figure 4. Ability of HTLV-1 Tax protein to modulate and thus
suppress the expression of cellular miRNAs. A miRNA microarray
cluster was used to demonstrate the ability of HTLV-1 Tax to globally
downregulate the expression of cellular miRNAs. The two lanes
represent the Cy5/Cy3 ratio in dye flip. The miRNAs isolated from the
stably integrated pooled Jurkat clone transfected with Tax were labeled
with Cy5 whereas those isolated from the same integrated clone but
transfected with control plasmid (pCMV4) were labeled with Cy3. The
table shows the high probability miRNAs against P/CAF and p300 that
have been downregulated in the presence of HTLV-1 Tax.
doi:10.1371/journal.pone.0034490.g004
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[76], two of which (miR-93 and miR-130b) targeted the 39 UTR
of the mRNA coding for a tumor suppressor protein, tumor
protein 53-induced nuclear protein 1. Other studies have found
several cancer-linked miRNAs (miRs 21, 24, 146a, 155, and 223)
to be deregulated in HTLV-1 transformed cells [77]. All of these
miRNAs were upregulated except miR-223, which was downreg-
ulated. Moreover, the expression of miR-146a was directly
stimulated by Tax via NF-kB-mediated transactivation of its
promoter. Analysis of hematopoietic-specific miRNAs found an
aberrant expression of miRs (223, 181a, 150, 142.3p, and 155) in
HTLV-1-infected cells in vitro and uncultured ex vivo ATL cells as
well as altered expression of miRNAs involved in innate immunity
regulation, particularly miRs (155, 125a, 132, and 146) [78]. On
comparing the expression of miR-146a in HTLV-1-infected and -
uninfected T-cell lines, Tax was found to induce the expression of
miR-146a in a NF-kB-dependent manner and inhibited the
expression of a gene harboring the target sequence of miR-146a
on its 39 UTR [79].
The miRNAs, like transcription factors, play a key role in the
regulatory events of the cell; however, unlike transcription factors
that can either positively or negatively regulate transcription,
miRNAs primarily work through repression. Moreover, the
miRNAs themselves are involved in regulating the expression of
many transcription factors [80]. The role of miRNAs in chromatin
remodeling, particularly in T-cell development and function, is a
current area of investigation [81]. Therefore, the miRNA pathway
serves as an ideal target for viruses that wish to control the
regulation of many crucial proteins intrinsic to viral replication
and survival as well as those that mediate antiviral effects. It is thus
not surprising that current studies are centered on the mechanism
by which retroviruses hijack and usurp the host miRNA processing
machinery. With the role of cellular miRNAs becoming evident in
various aspects of the viral life cycle, ranging from replication [82]
to latency [83], the need to focus on stages that are critical to viral
activation is important. Based on a recent study wherein HIV-1
was shown to suppress the expression of an miRNA linked to the
regulation of P/CAF [61], we proceeded to determine whether the
Figure 5. Down regulation of miR-149 and miR-873 in HTLV-1 infected cell line, MT-2. miR-873 were validated for their presence in MT-2
and Jurkat cells by real time PCR. Amplification plots were obtained for the same and plotted with their respective Ct values in both the cell lines with
GAPDH as internal control (A). Fold-change in the expression was calculated based on the DDCt method. Triplicate samples were utilized to derive
the standard deviation and significance by t-test represented here as * for p,0.05.
doi:10.1371/journal.pone.0034490.g005
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machinery and to verify whether any of the downstream targets of
the miRNAs affected by Tax modulation are involved in
chromatin remodeling. Because each cell type has its own
repertoire of miRNAs [70], the newly constructed CD4
+ T-cell
line with a stably integrated HTLV-1 LTR provided the ideal
model in which to examine the hypothesis.
The miRNA microarray results and the subsequent analysis
using the Web-based tool MicroInspector [62] clearly demon-
strated that, following the introduction of Tax into the cell with an
integrated viral promoter, there is downregulation of miRNAs that
are known to target mRNA members of the HAT family. Out of
nine miRNAs specific for P/CAF, three were significantly
downregulated (has-miRs-135b, 149, and 872). Similarly, out of
the 26 miRNAs specific for p300, three were substantially
downregulated (hsa-miRs-149, 872, and 873). In addition, a
myeloid-specific miRNA (hsa-miR-223), the expression of which
has been shown to be under the control of the transcription factor
C/EBP [84], known to be involved in granulopoiesis, was shown
to be downregulated and to be highly repressed in the
transcription factor array (Table 1). Moreover, the reduced level
of miR-223 is associated with an increase in the production,
differentiation, and activation of granulocytes that can lead to
tissue inflammation as well as leukemia [85]. This observation is
particularly exciting because it highlights the involvement of the
HTLV-1 transactivating protein Tax in the eventual modulation
of the host cellular miRNA pathway. Although the exact
mechanism by which Tax causes the observed downregulation
of the miRNAs is not known, it is possible that Tax could be acting
through the suppression of the type III RNases, Dicer (in
cytoplasm) and/or Drosha (in nucleus), that are involved in the
biogenesis and processing of miRNAs. The suppression of both of
these enzyme complexes could also account for the observed
global downregulated pattern following transfection with Tax.
With regard to HIV-1, the artificial repression of Dicer and
Drosha was shown not only to reduce the processing and
maturation of miRNAs but also to enhance HIV-1 replication
[61]. In another study, the use of RNA silencing suppressors to
mask the cellular RNAi in human cells resulted in increased HIV-
1 replication [86]. The transactivating proteins Tat and Tas of
HIV-1 and primate foamy virus type 1 (PFV-1), respectively, have
been shown to suppress the cellular miRNA-mediated silencing
[71,87]. These studies showcase the participation of the miRNA
pathway and its enzymes in repressing HIV-1 and also the ability
Figure 6. Effect of miRNA mimics on the expression of p300 and p/CAF in MT-2 cells. (A) Equal protein amounts from the whole cell lysates
of MT-2 and Jurkat cells lines were resolved on SDS polyacrylamide gel and then transferred to a PVDF membrane. The membrane was then
incubated with anti-p300 (1:1000 dilution) and anti-p/CAF (1:1000 dilution) monoclonal antibodies for 2 h at room temperature and incubated for 1 h
with an anti-rabbit secondary antibody conjugated to IRDy800 and IRDy680, respectively. Signals were detected by Licor Pearl Pulse Imager. It was
observed that the levels of p300 and p/CAF went down on transfection of MT-2 cells with respective miR-mimic when compared to non-transfected
MT-2 cells. (B) HTLV-1 p19 was quantitated with ELISA in MT-2 culture supernatant and compared to supernatant obtained from MT-2 cells
transfected with miR-149 and miR-873 mimics.
doi:10.1371/journal.pone.0034490.g006
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advantage. Although no such mechanism has yet been developed
for HTLV-1, we demonstrate herein the ability of the HTLV-1
transactivating protein Tax to modulate the cellular miRNA
machinery within the CD4
+ T cell containing a stably integrated
HTLV-1 LTR, resulting in a global downregulation of cellular
miRNAs, many of which are involved in the regulation of
chromatin remodeling HAT factors.
In order to validate our observations, we selected miR-149 and
miR-873 that were substantially down regulated and could
potentially target p/CAF and p300 based on the software analysis.
First, we detected their presence in Jurkat cells and observed
significant down regulation in MT-2 cells confirming our miRNA
array results in a HTLV-1 infected cell line. To further ensure that
these miRNAs could indeed target p/CAF and p300, we over-
expressed these in MT-2 cells and observed a sharp decline in the
expression of these chromatin-remodeling enzymes. Also, on
scoring for virus response, we found a decrease in the levels of viral
progeny production in trasfected cells. These observations are first
in line to support the virus-miRNA-chromatin concept and
require further in depth investigations to tease out the exact
molecular mechanisms that lead to viral latency or replication in a
given cell type.
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